Procysteine

Procysteine

SCHEMBL83023

O=C1NC(C(=O)O)CS1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Procysteine SCHEMBL352387 1.00
Procysteine SCHEMBL9139321 1.00 HTT (0.53)
Procysteine SCHEMBL1134004 1.00
Procysteine SCHEMBL10623235 0.98 HTT (0.52)
Procysteine SCHEMBL8428864 0.98 HTT (0.52)
Procysteine SCHEMBL4164380 0.98 HTT (0.52)
Procysteine SCHEMBL20822405 0.84 HTT (0.45)
Procysteine SCHEMBL1150486 0.84 HTT (0.45)
Procysteine SCHEMBL8040939 0.83 HTT (0.41)
Procysteine SCHEMBL1681501 0.80 PTGS1 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2633 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
EP-4632063-A2 COPPER LOSS MITIGATION GENENTECH, INC. (US) 2025-10-15 EP claimed
US-12428447-B2 Peptide-based non-proteinaceous cargo delivery FELDAN BIO INC. (CA) 2025-09-30 US claimed
EP-4136211-B1 COPPER LOSS MITIGATION GENENTECH INC (US) 2025-07-09 EP claimed
US-20250171739-A1 PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS JUNO THERAPEUTICS, INC. (US) 2025-05-29 US claimed
US-12258580-B2 Process for generating therapeutic compositions of engineered cells JUNO THERAPEUTICS, INC. (US) 2025-03-25 US claimed
EP-4512823-A2 PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS Juno Therapeutics, Inc. (US) 2025-02-26 EP claimed
EP-4468884-A1 LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT Amarin Pharmaceuticals Ireland Limited (IE) 2024-12-04 EP claimed
CN-118714935-A Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment 阿马里纳药物爱尔兰有限公司 2024-09-27 CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
EP-0494405-A2 Use of thiazolidine-4-carboxylate derivatives for the treatment of pulmonary diseases Transcend Therapeutics, Inc. (US) 1992-07-15 EP claimed
US-5095027-A Antiischemic CLINTEC NUTRITION CO. (US) 1992-03-10 US claimed
WO-1991016820-A1 PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1991-11-14 WO claimed
US-4665082-A ENZYMATIC HYDROLYSIS OF L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION (US) 1987-05-12 US claimed
US-4647571-A 2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION (US) 1987-03-03 US claimed
EP-0057942-B1 CYSTEINE DELIVERY SYSTEM Cornell Research Foundation (US) 1985-09-11 EP claimed
US-4438124-A ADMINISTERING L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION, INC. (US) 1984-03-20 US claimed
US-4434158-A INCREASING GLUTATHIONE LEVELS CORNELL RESEARCH FOUNDATION (US) 1984-02-28 US claimed
EP-0057942-A2 Cysteine delivery system Cornell Research Foundation (US) 1982-08-18 EP claimed
US-4335210-A ENZYMATIC HYDROLYSI OF 2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION (US) 1982-06-15 US claimed